TY - JOUR
T1 - Conducting omega-3 clinical trials with cardiovascular outcomes
T2 - Proceedings of a workshop held at ISSFAL 2014
AU - Rice, Harry B.
AU - Bernasconi, Aldo
AU - Maki, Kevin C.
AU - Harris, William S.
AU - von Schacky, Clemens
AU - Calder, Philip C.
N1 - Publisher Copyright:
© 2016 The Authors.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - In contrast to earlier long-chain (LC) omega-3 (i.e. EPA and DHA) investigations, some recent studies have not demonstrated significant effects of EPA and DHA on cardiovascular disease (CVD) outcomes. The neutral findings may have been due to experimental design issues, such as: maintenance on aggressive cardiovascular drug treatment overshadowing the benefits of LC omega-3s, high background LC omega-3 intake, too few subjects in the study, treatment duration too short, insufficient LC omega-3 dosage, increase in omega-6 fatty acid intake during the study, failure to assess the LC omega-3 status of the subjects prior to and during treatment and lack of clarity concerning which mechanisms were expected to produce benefits. At the 11th ISSFAL Congress, a workshop was held on conducting LC omega-3 clinical trials with cardiovascular outcomes, with the goal of gaining a better understanding concerning aspects of experimental design that should be considered when planning clinical studies related to EPA and DHA and potential cardiovascular benefits.
AB - In contrast to earlier long-chain (LC) omega-3 (i.e. EPA and DHA) investigations, some recent studies have not demonstrated significant effects of EPA and DHA on cardiovascular disease (CVD) outcomes. The neutral findings may have been due to experimental design issues, such as: maintenance on aggressive cardiovascular drug treatment overshadowing the benefits of LC omega-3s, high background LC omega-3 intake, too few subjects in the study, treatment duration too short, insufficient LC omega-3 dosage, increase in omega-6 fatty acid intake during the study, failure to assess the LC omega-3 status of the subjects prior to and during treatment and lack of clarity concerning which mechanisms were expected to produce benefits. At the 11th ISSFAL Congress, a workshop was held on conducting LC omega-3 clinical trials with cardiovascular outcomes, with the goal of gaining a better understanding concerning aspects of experimental design that should be considered when planning clinical studies related to EPA and DHA and potential cardiovascular benefits.
KW - Cardiovascular disease
KW - Design
KW - Docosahexaenic
KW - Eicosapentaenoic
KW - Omega-3
UR - http://www.scopus.com/inward/record.url?scp=84962052424&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84962052424&partnerID=8YFLogxK
U2 - 10.1016/j.plefa.2016.01.003
DO - 10.1016/j.plefa.2016.01.003
M3 - Article
C2 - 26858145
AN - SCOPUS:84962052424
SN - 0952-3278
VL - 107
SP - 30
EP - 42
JO - Prostaglandins Leukotrienes and Essential Fatty Acids
JF - Prostaglandins Leukotrienes and Essential Fatty Acids
ER -